# Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031

- Link: https://www.thailand-business-news.com/pr-news/frost-sullivan-global-pharmaceutical-industry-faces-a-high-stakes-reset-as-ai-biologics-and-supply-resilience-redefine-growth-through-2031
- Published: 2026-06-11T03:56:00+07:00
- Author: PR Newswire

_New Frost & Sullivan analysis reveals that future winners will be those that can
execute faster, industrialise innovation, and navigate mounting pricing and geopolitical
pressures_

LONDON, June 11, 2026 /PRNewswire/ — Frost & Sullivan’s latest analysis, _Growth
Opportunities in Global Pharmaceutical Industry, 2026_, finds that the pharmaceutical
industry is entering a period of profound transformation as affordability mandates,
patent expiries, geopolitical fragmentation, and rapid technological advances reshape
the foundations of value creation.

According to the study, traditional drivers of success are being replaced by a new
set of competitive imperatives centred on execution excellence, supply resilience,
AI-enabled operations, and the ability to commercialise increasingly complex therapeutic
modalities at scale.

"2026 marks a decisive reset for global biopharma," said **Surbhi Gupta, Industry
Principal at Frost & Sullivan**. "Commercial success will depend less on historical
peak-sales models and more on how quickly companies can generate evidence, secure
market access, integrate innovation, and reliably deliver advanced therapies in 
increasingly complex operating environments."

The analysis highlights five themes that will define the next phase of industry 
growth. Policy reforms, accelerating patent expiries, and intensifying pricing pressures
are compressing traditional value-capture windows, forcing organisations to generate
evidence earlier, strengthen lifecycle management strategies, and accelerate market
access efforts. At the same time, deliverability is emerging as a critical source
of competitive advantage, with manufacturing readiness, cold-chain integrity, quality
assurance, and site-of-care preparedness becoming essential differentiators in an
era of increasingly sophisticated therapies.

Innovation models are also evolving as pharmaceutical companies become more selective
in their investments, prioritising scalable assets, high-conviction opportunities,
and their ability to rapidly integrate and operationalise external innovation. Meanwhile,
supply resilience has shifted from an operational concern to a strategic imperative,
as governments and regulators place greater emphasis on localisation, continuity,
and security of supply amid geopolitical uncertainty. Finally, artificial intelligence
is moving beyond experimentation into governed, audit-ready workflows embedded across
discovery, clinical operations, quality, manufacturing, and commercial functions,
creating the foundations for more efficient and data-driven operating models.

Frost & Sullivan notes that growth opportunities are increasingly concentrated around
biologics and next-generation modalities, including GLP-1 therapies, antibody-drug
conjugates (ADCs), radioligand therapies, and cell and gene therapies, while surrounding
ecosystems such as obesity care operating systems, specialised manufacturing capabilities,
and confirmatory-ready clinical trial models offer significant whitespace opportunities.

The study also forecasts a divergence in growth trajectories between traditional
small molecules and large molecules. While small molecules will remain the industry’s
cash-flow backbone, biologics are expected to continue expanding their share of 
the market as companies invest in advanced therapeutic platforms and industrial-
scale execution capabilities.

"Pharma companies can no longer treat these pressures as a series of incremental
challenges," Gupta concludes. "The organisations that thrive will be those willing
to rebuild their operating models around resilience, speed, disciplined innovation,
and scalable execution."

To claim your complimentary extract from this Growth Opportunity Analysis, click
here: [https://shorturl.at/QABlD](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708731-1&h=1154136858&u=https%3A%2F%2Fshorturl.at%2FQABlD&a=https%3A%2F%2Fshorturl.at%2FQABlD)

To purchase the full report, please visit our store: [Pharmaceutical Industry Growth 2026 | Frost & Sullivan](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708731-1&h=1528978185&u=https%3A%2F%2Fstore.frost.com%2Fgrowth-opportunities-in-global-pharmaceutical-industry-2026.html&a=Pharmaceutical+Industry+Growth+2026+%7C+Frost+%26+Sullivan)

**About Frost & Sullivan**

Frost & Sullivan, the Transformational Growth Company, enables clients to accelerate
growth and achieve best-in-class positions in growth, innovation, and leadership.
The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational
strategies and best-practice models to drive the generation, evaluation, and implementation
of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered
with investors, corporate leaders, and governments to identify, prioritise, and 
execute transformational growth strategies.

Your Transformational Growth Journey Starts Here: [**Schedule Your Growth Pipeline Dialog™**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708731-1&h=1663950539&u=https%3A%2F%2Fgo.frost.com%2Fgpdialog%3Fcampaign_source%3Dglobal%26utm_medium%3DPR%26utm_source%3Dprnewswire&a=Schedule+Your+Growth+Pipeline+Dialog%E2%84%A2)
with the Frost & Sullivan team.

**Contact:

Kristina Menzefricke
Marketing & CommunicationsGlobal Customer Experience, Frost&
Sullivan[kristina.menzefricke@frost.com](https://www.thailand-business-news.com/pr-news/kristina.menzefricke@frost.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031 ](http://www.prnasia.com/story/archive/4980827_AE80827_0?rand=184833)
